Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CytoScan: Automated Detection of Technical Anomalies for Cytometry Quality Control.

Cytometry. Part A : the journal of the International Society for Analytical Cytology·2026
Same author

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Trials·2026
Same author

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

HemaSphere·2026
Same author

Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

American journal of hematology·2026
Same author

Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive 'real-world routine'.

British journal of haematology·2026

Related Experiment Video

Updated: Apr 15, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

861

Gene expression profiles associated with pediatric relapsed AML.

Costa Bachas1, Gerrit Jan Schuurhuis2, C Michel Zwaan3

  • 1Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.

Plos One
|April 8, 2015
PubMed
Summary
This summary is machine-generated.

Pediatric acute myeloid leukemia (AML) relapse is a major challenge. Gene expression profiling reveals that leukemic cells at relapse are biologically distinct from their initial diagnosis, offering new therapeutic targets.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

931
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

861
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

931
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.1K

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Relapse remains a significant obstacle in improving survival rates for pediatric acute myeloid leukemia (AML) patients.
  • Leukemic blast cell characteristics enabling initial survival, relapse development, and subsequent treatment resistance are not well understood.
  • Understanding biological differences between initial and relapsed AML is crucial for developing effective salvage therapies.

Purpose of the Study:

  • To investigate whether leukemic blast cells at relapse exhibit distinct biological characteristics compared to their initial diagnosis counterparts in pediatric AML.
  • To identify potential molecular mechanisms underlying treatment resistance and relapse in pediatric AML.

Main Methods:

  • Microarray gene expression profiling was performed on paired initial diagnosis and relapse samples from 23 pediatric AML patients.
  • Unsupervised analysis was used to compare gene expression profiles between paired samples.
  • Mutational status shifts were analyzed in conjunction with gene expression data.

Main Results:

  • Gene expression profiles differed between initial and relapse samples in 11 out of 23 patients, indicating significant biological alterations.
  • Shifts in type I/II mutational status were observed in a subset of patients with altered gene expression profiles.
  • Differentially expressed genes were commonly associated with hematopoietic differentiation, chromatin remodeling, and key transcription factors (CEBPA, GFI1, SATB1, KLF2, TBP).

Conclusions:

  • Leukemic blast cells at relapse are biologically different from those at initial diagnosis in pediatric AML.
  • These observed biological differences represent potential targets for the development of novel and more effective treatment strategies for relapsed AML.